---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-038570"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:31:30.768717+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avalo Q2 2025 net loss $20.8M; cash $113.3M; Phase 2 LOTUS >75% enrolled, topline mid-2026

## Summary
- Net loss of $20.8M in Q2 2025 ($1.92 per share) compared to net income of $98.5M ($4.21 basic EPS) in Q2 2024, driven by warrant-related items.
- Cash and short-term investments $113.3M as of June 30, 2025; expected to fund operations into 2028.
- Phase 2 LOTUS trial (AVTX-009 in hidradenitis suppurativa) enrollment >75% complete; topline data expected mid-2026.
- R&D expenses increased to $14.1M from $4.6M, largely due to the Phase 2 LOTUS trial.
- Rita Jain, M.D. appointed to Board of Directors; brings clinical development and regulatory experience.

## SEC filing metadata
- accession: 0001628280-25-038570
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828025038570/0001628280-25-038570-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828025038570/avtx-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-038570
- JSON: https://secwatch.observer/filing/0001628280-25-038570.json
- Plain text: https://secwatch.observer/filing/0001628280-25-038570.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.